Article

CXL cytotoxicity digs deep

Author(s):

Often forgotten in the buzz over corneal crosslinking (CXL) is that the procedure kills cells down to 300 µm deep, knocking out everything in its path, including microorganisms and keratocytes, said Theo Seiler, MD, PhD.

New Orleans-Often forgotten in the buzz over corneal crosslinking (CXL) is that the procedure kills cells down to 300 µm deep, knocking out everything in its path, including microorganisms and keratocytes, said Theo Seiler, MD, PhD.

"This is a powerful method of killing germs inside the cornea,” said Dr. Seller, professor of ophthalmology at the University of Zurich and chairman of IROC, Zurich. "The loss of cells is persistent-there is still a loss after 3 years.”

Dr. Seiler, who introduced CXL, said he sees tremendous applications for melting diseases.

"In these diseases, there is a constant thinning, a loss of tissue, but if you can delay that-or make the collagen more resistant-the equilibrium can shift between catalysis and synthesis to where there’s augmentation," he said.

Separate studies released this year in Iran and Europe continue to suggest that CXL is an effective procedure with long-term results, Dr. Seller said.    

Complication rates for these new studies ranged from 0% to 13%, with a failure rate of 2%. Other studies support these findings, as there is almost complete absence of adverse reactions to the treatment, he said.

During CXL, new chemical bonds are created between molecules, translating not only to well-documented stable bridges that reinforce the corneal structure, but also, as Dr. Seiler emphasized, making the collagen more resistant against digestive enzymes.

“It is not correct to call this procedure collagen crosslinking,” he said, “but corneal crosslinking, as the changes are not only in the skin collagen.”

 

For more articles in this issue of Ophthalmology Times Conference Brief click here.

 

To receive weekly clinical news and updates in ophthalmology, subscribe to the Ophthalmology Times eReport.

Newsletter

Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.

Related Videos
(Image credit: Ophthalmology Times) ASCRS 2025: Parag Majmudar, MD, on bridging the gap between residency and real-world practice
Brett Bielory, MD, discusses his poster at the ASCRS annual meeting, which focuses on an under-diagnosed corneal pathology: neurotrophic keratitis.
(Image credit: Ophthalmology Times) Oluwatosin U. Smith talks Glaukomtecken
ASCRS 2025: Eva Kim, MD, discusses implantable collamer lenses and high myopia.
Abby Markward, MBA, and Hattie Hayes, editor of Ophthalmology Times Europe, discuss the ASCRS and ASOA meetings
Abby Markward discusses the ASCRS Foundation and the ASCRS Annual Meeting
(Image credit: Ophthalmology Times) Inside ASCRS 2025: Francis S. Mah, MD, takes the helm with a vision for research, education, and advocacy
© 2025 MJH Life Sciences

All rights reserved.